Amgen & Sanofi
5 shared events · Importance 3 · Last updated Jul 29, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Amgen: Amgen is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Business
Amgen: Amgen's Repatha is a competitor to Scribe's STX-1150 in the PCSK9 inhibitor space. The success of Scribe's therapy could impact Amgen's market share in cholesterol management.
Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.
Jul 06, 2026 · 25 articles
Regulatory
Amgen: Competitor with injectable PCSK9 inhibitor Repatha; faces potential market share loss to oral alternative.
Sanofi: Co-marketer of Praluent; faces similar competitive pressure.
Jul 16, 2026 · 93 articles
Regulatory
Amgen: Amgen is one of the leading life sciences companies that has established or expanded R&D, digital, and global capability centers in Hyderabad, reflecting confidence in India — Telangana's ecosystem.
Jan 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Amgen and Sanofi interact across events, view sentiment trends, and discover connected entities.
Open Dashboard